Front Immunol:高中性粒细胞与淋巴细胞比值是终末期IgA肾病的独立危险因素

2022-01-26 从医路漫漫 MedSci原创

免疫球蛋白A肾病(IgAN)是世界范围内常见的原发性肾小球肾炎,其发生发展受多种因素的影响。

背景:免疫球蛋白A肾病(IgAN)是世界范围内常见的原发性肾小球肾炎,其发生发展受多种因素的影响。自身免疫和炎症被认为是其基本机制,但其确切发病机制尚不清楚。中性粒细胞/淋巴细胞比率(NLR)作为一种新的炎症标志物,已在多种疾病中得到研究。目前尚不清楚NLR能否预测IgAN患者的肾脏结局。我们评估了IgAN患者NLR与肾功能、病理损害、肾脏进展和预后的关系。

方法:对966例经活检证实的IgAN患者进行回顾性研究。根据NLR值分为高组(NLR2.6 7,n=384)和低组(≥<2.6 7,n=5 82)。终点为终末期肾病[估计肾小球滤过率(EGFR)<15mL/min/1.73m2或接受肾脏替代治疗]。对NLR与其他重要指标(EGFR、血肌酐、蛋白尿、高血压、肾脏病理损害)进行相关性检验。预测值由受试者工作特征曲线下面积(AUROC)决定。采用Kaplan-Meier和Cox比例风险分析评估肾脏进展和预后。

结果:NLR的AUROC最高,为0.633(P<0.001)。相关分析显示,NLR值与血肌酐(r=0.127,p<0.001)、24小时尿蛋白定量(r=0.18p<0.001)呈正相关,与表皮生长因子受体呈负相关(r=0.14p<0.001)。NLR值高的IgAN患者更易患高血压(p=0.003)。多因素Cox回归分析显示,即使在调整了重要的临床和病理参数后,高NLR值仍是IgAN的独立危险因素(p=0.043,HR=1.74,95%CI:1.0 2~2.97)。Kaplan-Meier分析显示,高NLR值与IgA肾病患者的肾脏预后显著相关(P<0.001),尤其是3~4期慢性肾病患者(P=0.028)或24小时尿蛋白定量>1g/d的患者(P<0.001)。

图1 NLR的ROC曲线下面积(AUC)。

表1 各种预测因素对IgAN患者终末期肾病诊断的准确性

表2 966例IgAN患者的人口学和临床病理特征

表3 966例IgAN患者肾脏预后的单因素和多因素Cox比例风险模型分析

图2 终末期肾病终点的不同类型Kaplan-Meier分析。(A)对所有患者进行Kaplan-Meier分析,直至终末期肾病(ESRD)终点。(B,C)对终末期肾病(ESRD)终点采用不同治疗方法的患者进行Kaplan Meier分析。(D-F)Kaplan-Meier分析对不同CKD分期到终末期的ESRD患者。(G,H)Kaplan-Meier分析不同尿蛋白患者的终末期肾病。

表4 966例患者治疗后NLR的变化

结论:NLR升高影响IgAN患者肾脏进展和预后,可作为评估肾功能和病理损害的指标。

原文出处:Wang S,  Dong L,  Pei G,et al.High Neutrophil-To-Lymphocyte Ratio Is an Independent Risk Factor for End Stage Renal Diseases in IgA Nephropathy.Front Immunol 2021;12

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1693517, encodeId=ddbb169351ec2, content=<a href='/topic/show?id=7e2de81588c' target=_blank style='color:#2F92EE;'>#终末期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78158, encryptionId=7e2de81588c, topicName=终末期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6429431807, createdName=anminleiryan, createdTime=Sat Apr 30 02:11:54 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037206, encodeId=1190203e206e4, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Thu Sep 01 14:11:54 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191202, encodeId=6d951191202c8, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:51:11 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296778, encodeId=e7211296e78d7, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302423, encodeId=8118130242371, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414615, encodeId=e9e514146156e, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503979, encodeId=dff915039e95b, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1693517, encodeId=ddbb169351ec2, content=<a href='/topic/show?id=7e2de81588c' target=_blank style='color:#2F92EE;'>#终末期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78158, encryptionId=7e2de81588c, topicName=终末期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6429431807, createdName=anminleiryan, createdTime=Sat Apr 30 02:11:54 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037206, encodeId=1190203e206e4, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Thu Sep 01 14:11:54 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191202, encodeId=6d951191202c8, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:51:11 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296778, encodeId=e7211296e78d7, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302423, encodeId=8118130242371, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414615, encodeId=e9e514146156e, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503979, encodeId=dff915039e95b, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1693517, encodeId=ddbb169351ec2, content=<a href='/topic/show?id=7e2de81588c' target=_blank style='color:#2F92EE;'>#终末期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78158, encryptionId=7e2de81588c, topicName=终末期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6429431807, createdName=anminleiryan, createdTime=Sat Apr 30 02:11:54 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037206, encodeId=1190203e206e4, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Thu Sep 01 14:11:54 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191202, encodeId=6d951191202c8, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:51:11 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296778, encodeId=e7211296e78d7, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302423, encodeId=8118130242371, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414615, encodeId=e9e514146156e, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503979, encodeId=dff915039e95b, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
    2022-02-08 ms3000000637975859

    很有用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1693517, encodeId=ddbb169351ec2, content=<a href='/topic/show?id=7e2de81588c' target=_blank style='color:#2F92EE;'>#终末期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78158, encryptionId=7e2de81588c, topicName=终末期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6429431807, createdName=anminleiryan, createdTime=Sat Apr 30 02:11:54 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037206, encodeId=1190203e206e4, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Thu Sep 01 14:11:54 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191202, encodeId=6d951191202c8, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:51:11 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296778, encodeId=e7211296e78d7, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302423, encodeId=8118130242371, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414615, encodeId=e9e514146156e, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503979, encodeId=dff915039e95b, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1693517, encodeId=ddbb169351ec2, content=<a href='/topic/show?id=7e2de81588c' target=_blank style='color:#2F92EE;'>#终末期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78158, encryptionId=7e2de81588c, topicName=终末期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6429431807, createdName=anminleiryan, createdTime=Sat Apr 30 02:11:54 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037206, encodeId=1190203e206e4, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Thu Sep 01 14:11:54 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191202, encodeId=6d951191202c8, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:51:11 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296778, encodeId=e7211296e78d7, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302423, encodeId=8118130242371, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414615, encodeId=e9e514146156e, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503979, encodeId=dff915039e95b, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1693517, encodeId=ddbb169351ec2, content=<a href='/topic/show?id=7e2de81588c' target=_blank style='color:#2F92EE;'>#终末期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78158, encryptionId=7e2de81588c, topicName=终末期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6429431807, createdName=anminleiryan, createdTime=Sat Apr 30 02:11:54 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037206, encodeId=1190203e206e4, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Thu Sep 01 14:11:54 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191202, encodeId=6d951191202c8, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:51:11 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296778, encodeId=e7211296e78d7, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302423, encodeId=8118130242371, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414615, encodeId=e9e514146156e, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503979, encodeId=dff915039e95b, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1693517, encodeId=ddbb169351ec2, content=<a href='/topic/show?id=7e2de81588c' target=_blank style='color:#2F92EE;'>#终末期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78158, encryptionId=7e2de81588c, topicName=终末期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6429431807, createdName=anminleiryan, createdTime=Sat Apr 30 02:11:54 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037206, encodeId=1190203e206e4, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Thu Sep 01 14:11:54 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191202, encodeId=6d951191202c8, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 20:51:11 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296778, encodeId=e7211296e78d7, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302423, encodeId=8118130242371, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414615, encodeId=e9e514146156e, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503979, encodeId=dff915039e95b, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Tue Jan 25 13:11:54 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
    2022-01-25 yibei

相关资讯

Front Immunol:尿可溶性CD163水平可以预测IgA肾病缓解状态

IgA肾病(IgAN)是最常见的原发性肾小球肾炎类型,也是慢性肾脏疾病(CKD)和肾衰竭的主要原因。

Sci Rep:静脉冲击注射甲基强的松龙联合小剂量强的松治疗高危IgA肾病

虽然IgAN的发病机制尚不完全清楚,但越来越多的证据表明,包括扁桃体感染和肠道感染在内的粘膜感染在IgAN的疾病进展中起着关键作用,遗传、环境和补体可能也参与了IgAN的发病机制。

KIDNEY INT REP:牛津分类法在IgA肾病类固醇治疗中的应用

将M1、E1、S1和C1+2分数定为SRS,T1+2分数定为SNR,总分可能是是否应使用类固醇治疗IgAN患者的良好指标。

Sparsentan治疗IgA肾病(IgAN),EMA已授予Sparsentan“孤儿药称号”

中期分析的初步结果表明,迄今为止,Sparsentan的耐受性良好,并且能够改善患者蛋白尿病症。

Clin J Am Soc Nephrol:成人肾移植术后IgA肾病的复发情况如何?

在IgA肾病导致的肾衰竭患者中,IgA沉积可在随后的肾脏移植中复发。复发性IgA肾病的临床病程是可变的,因为它可以在无症状的活检患者、轻度血尿或蛋白尿患者或肾功能迅速恶化的患者中诊断出来。因此,报告的

EBioMedicine:红细胞增多与IgA肾病有关

红细胞生成是一个严格控制的过程,适应成熟红细胞的生产,以供应器官的氧气。